Floatz logo

Telaglenastat

TNBC - Triple-Negative Breast Cancer

Calithera Biosciences, IncSmall moleculePhase 2Dormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
73/ 100

Competitive context

448 Active assets in the TNBC - Triple-Negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Capivasertib
AstraZeneca
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Famitinib
Fudan University
Phase 3BB

View all 50 →

Same molecule, other indications

Telaglenastat is also rated in:

Metastatic Lung Non-Small Cell CarcinomaDormant
BB
Indicative ·
65 / 100
View asset →
renal cell carcinomaDormant
B
Indicative ·
62 / 100
View asset →
nonpapillary renal cell carcinomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →